Article

SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma

Department of Microbiology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan
Blood (Impact Factor: 10.43). 03/2013; 121(18). DOI: 10.1182/blood-2012-07-441022
Source: PubMed

ABSTRACT Previously, we have shown that an AP-1 family member, FRA-2, is constitutively expressed in adult T-cell leukemia/lymphoma (ATL) and, together with JUND, upregulates CCR4 and promotes ATL cell growth. Among the identified potential target genes of FRA-2/JUND was SOX4. Here, we examine the expression and function of SOX4 in ATL. SOX4 was indeed consistently expressed in primary ATL cells. FRA-2/JUND efficiently activated the SOX4 promoter via an AP-1 site. Knockdown of SOX4 expression by small interfering RNA (siRNA) strongly suppressed cell growth of ATL cell lines. Microarray analyses revealed that SOX4 knockdown reduced the expression of genes such as germinal center kinase related (GCKR), NAK-associated protein 1 (NAP1), and histone deacetylase 8 (HDAC8). We confirmed consistent expression of GCKR, NAP1, and HDAC8 in primary ATL cells. We also showed direct activation of the HDAC8 promoter by SOX4. Furthermore, siRNA knockdown of GCKR, NAP1, and HDAC8 each significantly suppressed cell growth of ATL cell lines. Taken together, we have revealed an important oncogenic cascade involving FRA-2/JUND and SOX4 in ATL, which leads to the expression of genes such as GCKR, NAP1, and HDAC8.

0 Followers
 · 
80 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis of mantle cell lymphoma (MCL) can be difficult, especially when no t(11;14) translocation and cyclin D1 overexpression can be detected. In such cases, the transcription factor SOX11 represents an important diagnostic marker, as it is expressed in most MCLs and, in particular, in all cyclin D1-negative MCLs reported so far. A reliable anti-SOX11 antibody is therefore a very useful tool for routine diagnosis. Here, we characterize the new monoclonal anti-SOX11 antibodies, suitable for Western blot assay and immunohistochemistry (IHC) on formalin-fixed paraffin-embedded tissue; we tested them on a large series of primary lymphoid tumors and compared these results with those of other routinely used antibodies. Moreover, we show that IHC results depend on transcription levels of SOX11, which suggests that posttranscriptional and posttranslational modifications do not significantly affect cutoff levels for IHC detection of SOX11.
    The American journal of surgical pathology 10/2013; DOI:10.1097/PAS.0b013e3182a43996 · 4.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transcription factor Sox4 possesses an indispensable role in the development of early progenitor B cells from hematopoietic stem cells. However, its role in B-cell acute lymphoblastic leukemia, a malignant counterpart of normal progenitor B cells, is not fully understood. Here we showed that SOX4 is highly expressed in human acute lymphoblastic leukemia cells. To systematically study the function of Sox4 in acute lymphoblastic leukemia, we established a genetically defined mouse leukemia model by transforming progenitor B cells carrying a floxed Sox4 allele and inducing deletion of the allele by the self-excising Cre recombinase. This model allowed us to work with two groups of leukemic cells that had either one copy or both copies of Sox4 deleted. We found that depletion of Sox4 in transformed cells in vitro reduced the cell growth in vitro and the progression of leukemia in vivo. Moreover, depletion of Sox4 in leukemic cells in vivo prolonged the survival of the mice, suggesting that it could be a potential target in acute lymphoblastic leukemia therapy. Our microarray and bioChIP studies revealed that Tcf7l1 was the key Sox4 directly regulated gene. Knockdown of Tcf7l1 reduced cell proliferation, like the knockout of Sox4, and ectopic expression of Tcf7l1 could reverse the effect of Sox4 knockout on cell proliferation. These data suggest that Sox4 and Tcf7l1 is a functional axis that promotes the progression of BCR-ABL+ acute lymphoblastic leukemia.
    Haematologica 07/2014; DOI:10.3324/haematol.2014.104695 · 5.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chemokines and chemokine receptors orchestrate cell migration and homing in the body. Humans have at least 44 chemokines that are further classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C and CX3C. All the known chemokine receptors are seven transmembrane-type receptors. Humans have 18 chemotactic and 5 atypical non-chemotactic (recycling or scavenging) receptors. CCR4 is the receptor for two CC chemokines, CCL17 (also called "thymus and activation-regulated chemokine"/TARC) and CCL22 (macrophage-derived chemokine/MDC). Among the various T cell subsets, CCR4 is predominantly expressed by type 2 helper T cells (Th2 cells), cutaneous lymphocyte antigen (CLA)-positive skin-homing T cells, and regulatory T cells (Treg cells). Thus, CCR4 attracts much attention for its possible clinical applications in diseases involving these T cell subsets. Furthermore, CCR4 is often highly expressed by mature T cell neoplasms such as adult T-cell leukemia/lymphoma (ATL) and cutaneous T-cell lymphomas (CTCLs). This article is a brief overview of basic and clinical research on CCR4 and its ligands, which has eventually led to the development of a humanized defucosylated anti-CCR4 antibody "Mogamulizumab" for treatment of relapsed/refractory ATL and CTCLs.
    International Immunology 08/2014; 27(1). DOI:10.1093/intimm/dxu079 · 3.18 Impact Factor